Novartis loses latest bid to block generic version of blockbuster heart drug
Novartis has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by ...
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
Not every company is jumping onto the bandwagon and investing into weight loss drugs, however. One of the largest healthcare ...
Consumer groups ask FTC to block Novo Holdings-Catalent deal
U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, ...
BioSpace21h
NJ Court Tosses Novartis’ Lawsuit Against Drug Negotiation Program in Latest Setback for Big Pharma
With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies ...
Novartis Gets CHMP Recommendation for Kisqali in Broader Population
The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.
FiercePharma4d
Novartis falls short in legal effort to undo FDA approval of MSN's Entresto generic
As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss ...
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug
European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data ...
FierceBiotech4d
Novartis pays China's Baiyu $70M upfront, with $1.1B chaser, for small molecule cancer candidate
Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing ...
emjreviews.com2h
Heterogeneity of Inflammatory Processes and Pathways Driving Chronic Obstructive Pulmonary Disease Pathology
A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...
FierceBiotech7d
Novartis channels Gargamel, terminating midphase SMURF1 trial
Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will ...
FiercePharma11d
Novartis freed from Swiss antitrust probe over Cosentyx patent strategy
Two years after raiding the offices of Novartis, Switzerland’s Competition Commission (COMCO) has dropped its investigation ...